TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32093557

Group type: EXPERIMENTAL
Intervention: Prophylactic passive peritoneal drain
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no peritoneal drain)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prophylactic passive peritoneal drain and Control
Number of subjects: 25
Study: 35527578

Group type: EXPERIMENTAL
Intervention: AMT‐EST (Ankle Movement Training with Electrical Stimulation)
Number of subjects: 35

Group type: COMPARATOR
Intervention: EST (Electrical Stimulation)
Number of subjects: 35
Study: 33907267

Group type: EXPERIMENTAL
Intervention: 3% Diquafosol (DQS) used six times daily after cataract surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.1% Sodium Hyaluronate (HA) used six times daily after cataract surgery
Number of subjects: 0
Study: 33492667

Group type: EXPERIMENTAL
Intervention: Eclampsia
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Preeclampsia complicated by pulmonary edema
Number of subjects: 153

Group type: COMPARATOR
Intervention: Normotensive pregnancies
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Preeclampsia without severe features
Number of subjects: 153
Study: 616703485

Group type: EXPERIMENTAL
Intervention: Fast-Track (FT) protocol
Number of subjects: 63

Group type: COMPARATOR
Intervention: Conventional (CON) protocol
Number of subjects: 63
Study: 36058007

Group type: EXPERIMENTAL
Intervention: 600 mg of ginger extract daily for 3 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 66
Study: 33829804

Group type: EXPERIMENTAL
Intervention: Positive affect intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control
Number of subjects: 97
Study: 32896390

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg daily)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 915
Study: 36192779

Group type: EXPERIMENTAL
Intervention: EMA plus visualization platform for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: EMA alone for 7 days
Number of subjects: 50
Study: 33764282

Group type: EXPERIMENTAL
Intervention: IDD group
Number of subjects: 6
Study: 33142495

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 2,760 IU/kg
Number of subjects: 390

Group type: COMPARATOR
Intervention: Vitamin D3 at 5,520 IU/kg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Vitamin D3 at 2,760 IU/kg plus 25OHD at 2,760 IU (69 μg)/kg
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 25OHD
Number of subjects: 390
Study: 35380078

Group type: EXPERIMENTAL
Intervention: Continuous siponimod 2 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-siponimod group
Number of subjects: 0
Study: 34755994

Group type: EXPERIMENTAL
Intervention: 20 ml of normal saline 0.9% as irrigation solution (Group A)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 40 ml of normal saline 0.9% as irrigation solution (Group B)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: 60 ml of normal saline 0.9% as irrigation solution (Group C)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 330
Study: 32243029

Group type: EXPERIMENTAL
Intervention: Health Belief Model based nursing interventions offered at home visits
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 72
Study: 34499002

Group type: EXPERIMENTAL
Intervention: Silver nitrate application
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Silicone stent insertion
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 155
Study: 34618202

Group type: EXPERIMENTAL
Intervention: Nicotine (7 mg/24 h)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Nicotine (0.1 and 0.2 mg/kg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 72

Group type: COMPARATOR
Intervention: Vehicle administration
Number of subjects: 72
Study: 32956446

Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month dual anti-platelet therapy (DAPT)
Number of subjects: 14576

Group type: COMPARATOR
Intervention: 12-month aspirin monotherapy following 12-month DAPT
Number of subjects: 14576

Group type: EXPERIMENTAL
Intervention: 23-month ticagrelor monotherapy following 1-month DAPT
Number of subjects: 14576

Group type: EXPERIMENTAL
Intervention: Both anti-platelet strategies
Number of subjects: 14576
Study: 34008425

Group type: EXPERIMENTAL
Intervention: Perioperative pembrolizumab with chemotherapy (KEYNOTE-866)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (KEYNOTE-905/EV-303)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus enfortumab vedotin (KEYNOTE-905/EV-303)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radical cystectomy plus pelvic lymph node dissection alone (KEYNOTE-905/EV-303)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo with chemotherapy (KEYNOTE-866)
Number of subjects: 0
Study: 32388527

Group type: EXPERIMENTAL
Intervention: Piezosurgery for flap elevation (PFG)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Piezosurgery for osteotomy and odontosection (POG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional technique (CG)
Number of subjects: 20
Study: 35527411

Group type: EXPERIMENTAL
Intervention: Adaptive biofeedback training combined with oral administration of compound polyethylene glycol 4000-electrolyte powder
Number of subjects: 155

Group type: COMPARATOR
Intervention: Oral administration of compound polyethylene glycol 4000-electrolyte powder alone
Number of subjects: 155
Study: 34517840

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.25 µg/mL)
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 712
Study: 32086949

Group type: EXPERIMENTAL
Intervention: Medical Doctors (MDs) without dementia at baseline
Number of subjects: 3460

Group type: COMPARATOR
Intervention: General population
Number of subjects: 3460
Study: 35534628

Group type: EXPERIMENTAL
Intervention: SRR + PACERR
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRR
Number of subjects: 40
Study: 34965860

Group type: EXPERIMENTAL
Intervention: ePRO tool (mobile application and web portal)
Number of subjects: 13
Study: 35342437

Group type: EXPERIMENTAL
Intervention: Olibanum extract orally disintegrating tablets (ODT), 4 times a day for 3 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo orally disintegrating tablets (ODT), 4 times a day for 3 days
Number of subjects: 50
Study: 32381556

Group type: EXPERIMENTAL
Intervention: mPATH-CRC (iPad patient decision aid)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: mPATH-CRC
Number of subjects: 408
Study: 35328871

Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined Strength Training and Electromyostimulation (STEMS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study: 33208831

Group type: EXPERIMENTAL
Intervention: morphine (0.08 mg/kg) after undisturbed sleep (US)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: morphine (0.08 mg/kg) after forced awakening (FA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo after undisturbed sleep (US)
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo after forced awakening (FA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: morphine after forced awakening (FA) in females
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: morphine after forced awakening (FA) in males
Number of subjects: 100
Study: 34565172

Group type: EXPERIMENTAL
Intervention: C‐LIFE (Center‐Based Lifestyle Intervention)
Number of subjects: 140
Study: 32409493

Group type: EXPERIMENTAL
Intervention: RYGB + ET (combined aerobic and resistance exercise training program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: RYGB (standard of care)
Number of subjects: 0
Study: 35012992

Group type: EXPERIMENTAL
Intervention: Superficial cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intermediate cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Deep cervical plexus block (20 mL of 0.5% ropivacaine)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 34461584

Group type: EXPERIMENTAL
Intervention: Education intervention focusing on nutrition, hygiene, and child stimulation, combined with routine health care.
Number of subjects: 511

Group type: COMPARATOR
Intervention: Routine health care only (Control group).
Number of subjects: 511
Study: 33618015

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 36

Group type: COMPARATOR
Intervention: TTM
Number of subjects: 36

Group type: COMPARATOR
Intervention: NTC
Number of subjects: 36
Study: 33153145

Group type: COMPARATOR
Intervention: No mask
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cloth mask
Number of subjects: 14
Study: 35617440

Group type: EXPERIMENTAL
Intervention: 150 mg aspirin
Number of subjects: 190

Group type: COMPARATOR
Intervention: 80 mg aspirin
Number of subjects: 190
Study: 33509132

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting RV dysfunction including N-terminal pro-brain natriuretic peptide, cardiac troponin I, and ventricular diameter ratios
Number of subjects: 845
Study: 32799814

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg/kg)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Tramadol (2 mg/kg)
Number of subjects: 492
Study: 36269141

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis BS50 (2 × 10^9 CFU per day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 32569281

Group type: EXPERIMENTAL
Intervention: Having the kitchen in the same living house
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Iron intake less than 180 tablets
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Maternal weight gain during second and third trimester less than 6.53 kg
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Co‐morbidity during pregnancy
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Preterm birth
Number of subjects: 369
Study: 35255067

Group type: EXPERIMENTAL
Intervention: Multimedia education
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Face-to-face education
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no additional education)
Number of subjects: 135
Study: 34170930

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention or metformin (850mg twice daily)
Number of subjects: 317

Group type: COMPARATOR
Intervention: No treatment (placebo)
Number of subjects: 317
Study: 32707429

Group type: EXPERIMENTAL
Intervention: DXP (direct exposure; mares housed adjacent to stallion and allowed direct contact for 2 h for 3 d/wk)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IXP (indirect exposure; mares housed in an adjacent pen to the stallion but not allowed direct contact)
Number of subjects: 21

Group type: COMPARATOR
Intervention: CON (control; mares housed away from stallion and not allowed direct or indirect exposure)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: DXP (direct exposure)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 21
Study: 35349576

Group type: EXPERIMENTAL
Intervention: PharmQuit (intervention group)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 156
Study: 33271498

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Cognitively demanding exercise intervention
Number of subjects: 856

Group type: COMPARATOR
Intervention: Regular physical education program (Control)
Number of subjects: 856

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (independently of group)
Number of subjects: 856
Study: 36062600

Group type: EXPERIMENTAL
Intervention: Upper and lower Memotain® bonded retainers
Number of subjects: 68

Group type: COMPARATOR
Intervention: Upper and lower Ortho‐FlexTech™ bonded retainers
Number of subjects: 68
Study: 34624173

Group type: EXPERIMENTAL
Intervention: Community ART delivery
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Community-based visits
Number of subjects: 150
Study: 35870888

Group type: EXPERIMENTAL
Intervention: Teach-back health education (TBHE) based on WeChat mini-programs
Number of subjects: 59

Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 59
Study: 34912206

Group type: EXPERIMENTAL
Intervention: Exergame intervention group (Dividat Senso, 5 days per week)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exergame intervention group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard rehabilitation treatment)
Number of subjects: 39
Study: 32290344

Group type: EXPERIMENTAL
Intervention: RP-G28
Number of subjects: 377

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study: 33155484

Group type: EXPERIMENTAL
Intervention: Therapeutic exercise with Kinesio tape
Number of subjects: 120

Group type: COMPARATOR
Intervention: Therapeutic exercise alone
Number of subjects: 120
Study: 32034028

Group type: EXPERIMENTAL
Intervention: Luseogliflozin 2.5 mg once daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: DPP-4 inhibitor
Number of subjects: 60
Study: 35728573

Group type: EXPERIMENTAL
Intervention: Cognitively-engaging physical activity (18 sessions)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Free play (non-cognitively-engaging PA)
Number of subjects: 75
Study: 32570700

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35250307

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided thoracic paravertebral block with 0.33% ropivacaine (T group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline (C group)
Number of subjects: 60
Study: 32886828

Group type: EXPERIMENTAL
Intervention: Wu Qin Xi Qigong (WQXQ) exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional physical therapy (control group)
Number of subjects: 0
Study: 34610600

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34011002

Group type: EXPERIMENTAL
Intervention: SoundBite bone conduction device
Number of subjects: 18
Study: 36404985

Group type: EXPERIMENTAL
Intervention: Chewing gum in addition to standard therapy
Number of subjects: 258

Group type: COMPARATOR
Intervention: Standard therapy (Ondansetron 4 mg IV intra-operatively)
Number of subjects: 258
Study: 34028940

Group type: EXPERIMENTAL
Intervention: Glenohumeral mobilizations
Number of subjects: 121
Study: 36265048

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control (WLC)
Number of subjects: 42
Study: 32359936

Group type: EXPERIMENTAL
Intervention: Nanoemulsion eye drop
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-emollient eye drop
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nanoemulsion eye drop (used for 1 month, four times daily)
Number of subjects: 20
Study: 32078353

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Inreach (one-on-one education)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Outreach (mailed FIT)
Number of subjects: 673

Group type: EXPERIMENTAL
Intervention: Combination of inreach and outreach
Number of subjects: 673
Study: 32343960

Group type: EXPERIMENTAL
Intervention: JNJ-6379 (25 mg, 75 mg, 150 mg, or 250 mg daily for 4 weeks)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: JNJ-6379 (any dose)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: JNJ-6379 (150 mg)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 35263680

Group type: EXPERIMENTAL
Intervention: 40 mg/day ifenprodil tartrate for 4 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 33180816

Group type: EXPERIMENTAL
Intervention: Naloxone (3.25 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study: 35907828

Group type: EXPERIMENTAL
Intervention: Diet plus exercise program (6 consultations via videoconference, 50–75 min each, ketogenic very low‐calorie diet with meal replacements)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Exercise program (6 consultations via videoconference, 20–30 min each, strengthening exercise program, physical activity plan, educational/exercise resources)
Number of subjects: 88
Study: 34028042

Group type: EXPERIMENTAL
Intervention: Assertiveness training through hybrid education model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no assertiveness training)
Number of subjects: 0
Study: 32928957

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg once daily
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg once daily
Number of subjects: 191

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study: 36161964

Group type: EXPERIMENTAL
Intervention: HPV self-test kit
Number of subjects: 376
Study: 33298117

Group type: EXPERIMENTAL
Intervention: Daily use of the Insight Timer meditation app for 10 minutes daily for 30 days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no usage of meditation app)
Number of subjects: 150
Study: 35121137

Group type: EXPERIMENTAL
Intervention: Two additional intensive oral hygiene appointments before and after GA
Number of subjects: 408

Group type: COMPARATOR
Intervention: Standard care (control group) without additional appointments
Number of subjects: 408
Study: 33719774

Group type: EXPERIMENTAL
Intervention: Perioperative ureteral stenting (n = 24, 31.6%)
Number of subjects: 76

Group type: COMPARATOR
Intervention: No perioperative ureteral stenting (n = 52, 68.4%)
Number of subjects: 76
Study: 35218064

Group type: EXPERIMENTAL
Intervention: Home-Centered Cognitive Development Support Program
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 32833560

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor blockade using exendin-(9,39)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weight-matched controls
Number of subjects: 0
Study: 34228974

Group type: EXPERIMENTAL
Intervention: Aortic valve repair (AVr)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Aortic valve replacement (AVR)
Number of subjects: 417
Study: 34196903

Group type: EXPERIMENTAL
Intervention: Isolated concentric resistance exercise (CON) 3/week for 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isolated eccentric resistance exercise (ECC) 3/week for 8 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isolated concentric resistance exercise (CON)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isolated eccentric resistance exercise (ECC)
Number of subjects: 37
Study: 36199780

Group type: COMPARATOR
Intervention: Hormone group (prednisone acetate, n = 34)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination group (Ginkgo‐Damole combined with prednisone acetate, n = 30)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 64
Study: 36420979

Group type: EXPERIMENTAL
Intervention: R40/E10
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: R20/E10
Number of subjects: 452

Group type: COMPARATOR
Intervention: R10/E10
Number of subjects: 452

Group type: COMPARATOR
Intervention: R40
Number of subjects: 452

Group type: COMPARATOR
Intervention: R20
Number of subjects: 452
Study: 34902182

Group type: EXPERIMENTAL
Intervention: In-phase theta tACS
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 0
Study: 34393856

Group type: EXPERIMENTAL
Intervention: Single infusion of ketamine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline HR
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HR during the night (2-3 a.m.)
Number of subjects: 32
Study: 35728658

Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg (up to 2 doses separated by 10 minutes)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Etripamil 70 mg
Number of subjects: 500
Study: 34968107

Group type: EXPERIMENTAL
Intervention: Alcohol (blood alcohol concentration [BAC] = .075%)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Water control
Number of subjects: 135
Study: 32568929

Group type: EXPERIMENTAL
Intervention: Aphakia with contact lens correction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aphakia with spectacles
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aphakia with no correction
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aphakia (overall)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Aphakic eyes
Number of subjects: 57
Study: 32335316

Group type: EXPERIMENTAL
Intervention: SBAR-based program
Number of subjects: 54

Group type: COMPARATOR
Intervention: Handoff group
Number of subjects: 54
Study: 33069120

Group type: EXPERIMENTAL
Intervention: Normalized Grip Strength (NGS, kg/kg)
Number of subjects: 24109

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 24109
Study: 32311398

Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg QD
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: PF-06700841 60 mg QD
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: PF-06700841 10 mg QD
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: PF-06700841 30 mg QD (maintenance)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: PF-06700841 100 mg once weekly
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 35245081

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 14)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 16)
Number of subjects: 30
Study: 32833483

Group type: EXPERIMENTAL
Intervention: Mindfulness combined with interoceptive exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing mindfulness interventions
Number of subjects: 0